// App-Quantinova.ai

e14545 : The use of rituximab to manage B cell-mediated autoimmune thrombocytopenia (AITP) during concurrent program death ligand-1 (PD-L1) immunotherapy.

Researchers

Presenter

  • Michael Castro

Principal Investigators

  • N/A

Medical Centers

  • Personalized Cancer Medcn PLLC, Honolulu, HI

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Clear-cell adenocarcinoma

  • Thrombocytopenia

  • Solid malignancies

  • Immune thrombocytopenia

Biomarkers

  • Programmed death-ligand 1

  • Carbohydrate antigen 125

Drug/Treatment

  • Nivolumab

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved